Arbutus Q3 2021 Earnings Report
Key Takeaways
Arbutus Biopharma Corporation reported a net loss attributable to common shares of $24.2 million for the third quarter of 2021. The company's cash, cash equivalents, and investments totaled $151.9 million as of September 30, 2021, which they believe is sufficient to fund operations into the second quarter of 2023.
On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021
First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog (“NA”) therapy
On-track to initiate several proof-of-concept Phase 2a clinical trials with AB-729 as a cornerstone agent in combination with other approved or investigational compounds
Commenced IND enabling studies for Arbutus’ oral PD-L1 program
Arbutus
Arbutus
Forward Guidance
Arbutus believes its cash, cash equivalents and investments in marketable securities of $151.9 million as of September 30, 2021 are sufficient to fund the Company’s operations into the second quarter of 2023.